Immunization of chimpanzees with hepatitis B virus-derived polypeptides

Area of Science:

• Immunology
• Virology
• Vaccine Development

Background:

• Hepatitis B surface antigen (HBsAg)-associated 22-nm particles contain polypeptides that induce immunity.
• Previous studies in guinea pigs showed these polypeptides elicit humoral and cellular immune responses against HBsAg.

Purpose of the Study:

• To evaluate the immunogenicity and efficacy of a vaccine composed of purified HBsAg-associated polypeptides.
• To determine if these polypeptides can induce protective immunity against hepatitis B virus (HBV) infection in nonhuman primates.

Main Methods:

• Two major HBsAg polypeptides (P22 and P25) were isolated and adsorbed to alum adjuvant.
• Four nonimmune chimpanzees were immunized with the alum-adsorbed polypeptide vaccine.
• Vaccinated chimpanzees were subsequently challenged with a high dose of HBV.

Main Results:

• All vaccinated chimpanzees showed a strong anti-HBs antibody response after initial vaccination.
• Booster inoculations shifted the antibody response from IgM to IgG, indicating immunological memory.
• Following HBV challenge, none of the vaccinated chimpanzees developed markers of active infection or hepatitis.

Conclusions:

• The HBsAg polypeptide vaccine is immunogenic and elicits protective immunity against HBV infection in chimpanzees.
• The vaccine effectively establishes immunological memory, crucial for long-term protection.
• These findings support the potential of HBsAg-derived polypeptides as a basis for an effective hepatitis B vaccine.